IPP Bureau
T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy
By IPP Bureau - June 15, 2026
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026
By IPP Bureau - June 15, 2026
The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services
Ajanta Pharma to hold 47th annual general meeting on July 16
By IPP Bureau - June 15, 2026
Company sets key dates for shareholder participation and voting as it prepares to present FY26 annual report.
Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
By IPP Bureau - June 14, 2026
Samelisant will be the centerpiece of Suven’s scientific presence
Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio
By IPP Bureau - June 14, 2026
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Breakthrough approval in prostate cancer for AstraZeneca therapy
By IPP Bureau - June 14, 2026
The decision was driven by results from the Phase III CAPItello-281 trial,
India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test
By IPP Bureau - June 14, 2026
Cervical cancer remains one of the leading causes of cancer deaths among women in India
Centre intensifies push for zero leprosy transmission
By IPP Bureau - June 13, 2026
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
India validates first indigenous HPV DNA test for cervical cancer screening
By IPP Bureau - June 13, 2026
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
Ryvu advances romaciclib program as FDA clears AML trial expansion
By IPP Bureau - June 13, 2026
The regulatory decision follows promising results from RIVER-81
Novo Nordisk confirms cyber breach after hackers access personal data
By IPP Bureau - June 13, 2026
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
UK approves Wegovy pill in major shift in obesity treatment options
By IPP Bureau - June 13, 2026
Approval is based on results from the phase 3 OASIS 4 clinical trial
FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment
By IPP Bureau - June 13, 2026
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Rayat Bahra University, Shukra Pharma launch Rs. 10 lakh seed fund to back student startups
By IPP Bureau - June 13, 2026
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor
By IPP Bureau - June 13, 2026
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
